PTGS2 and myeloid sarcoma: Indeed, this latter study prompted our analysis of the effect of MMF on IEC, based on the postulate that triggering of inflammation in the gut through MMF signaling via the HCAR2/COX-2 pathway could also be responsible for the gastro-intestinal inflammation occurring in the initial phase of DMF therapy in MS patients (13, 54).